dc.contributor.author | Mumcu, Gonca | |
dc.contributor.author | Yay, Meral | |
dc.contributor.author | Aksoy, Aysun | |
dc.contributor.author | Taş, Mehmet Nedim | |
dc.contributor.author | Armağan, Berkan | |
dc.contributor.author | Sarı, Alper | |
dc.contributor.author | Bozca, Burçin Cansu | |
dc.contributor.author | Tekgöz, Emre | |
dc.contributor.author | Temiz Karadağ, Duygu | |
dc.contributor.author | Badak, Suade Özlem | |
dc.contributor.author | Tecer, Duygu | |
dc.contributor.author | Bes, Cemal | |
dc.contributor.author | Şahin, Ali | |
dc.contributor.author | Karadağ, Ömer | |
dc.contributor.author | Aksu, Kenan | |
dc.contributor.author | Keser, Gökhan | |
dc.contributor.author | Alibaz-Öner, Fatma | |
dc.contributor.author | İnanç, Nevsun | |
dc.contributor.author | Ergun, Tülin | |
dc.contributor.author | Direskeneli, Haner | |
dc.date.accessioned | 2021-03-18T12:45:04Z | |
dc.date.available | 2021-03-18T12:45:04Z | |
dc.date.issued | 2020-02-23 | |
dc.identifier.citation | Mumcu G, Yay M, Aksoy A, Taş MN, Armağan B, Sarı A, Bozca BC, Tekgöz E, Karadağ DT, Badak SÖ, Tecer D, Bes C, Şahin A, Erken E, Cefle A, Çınar M, Yılmaz S, Karaçaylı Ü, Alpsoy E, Şenel S, Yaşar Bilge Ş, Kaşifoğlu T, Karadağ Ö, Aksu K, Keser G, Alibaz-Öner F, İnanç N, Ergun T, Direskeneli H. Predictive factors for work-day loss in Behçet's syndrome: A multi-center study. Int J Rheum Dis. 2020 Feb;23(2):240-246. doi: 10.1111/1756-185X.13771. Epub 2019 Dec 19. PMID: 31858715. | tr_TR |
dc.identifier.uri | https://pubmed.ncbi.nlm.nih.gov/31858715/ | |
dc.identifier.uri | https://doi.org/10.1111/1756-185X.13771 | |
dc.identifier.uri | https://onlinelibrary.wiley.com/doi/full/10.1111/1756-185X.13771 | |
dc.identifier.uri | http://hdl.handle.net/11655/23584 | |
dc.description.abstract | Objective: The aim of this multi-center study was to assess predictive factors for work-day loss as an indirect cost element in Behçet's syndrome (BS).
Methods: In this cross-sectional, multi-center study, 834 BS patients (F/M: 441/393, age mean: 38.4 ± 10.9 years) were included. Data were collected by a questionnaire regarding treatment protocols, disease duration, smoking pattern, frequency of medical visits during the previous year and self-reported work-day loss during the previous year.
Results: Work-day loss was observed in 16.2% of patients (M/F: 103/32). The percentages of being a smoker (81.8%), using immunosuppressive (IS) medications (82%), and having disease duration <5 years (74%) were higher in male patients with work-day loss (P < .05). The majority of males (90.9%) had more than four clinic visits during the previous year. Moreover, the mean work-day loss (30.8 ± 57.7 days) was higher in patients with vascular involvement (56.1 ± 85.9) than those without (26.4 ± 50.6 days) (P = .046). In addition, increased frequency of ocular involvement (25.9%) was also observed in patients with work-day loss compared to others (8.6%) (P = .059).
Conclusion: Work-day loss was associated with both vascular and ocular involvement. Close associations were observed among male gender, early period of the disease, frequent medical visits, being a smoker and treatment with IS medications in patients with work-day loss. | tr_TR |
dc.language.iso | en | tr_TR |
dc.publisher | Wiley | tr_TR |
dc.relation.isversionof | 10.1111/1756-185X.13771 | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | tr_TR |
dc.rights.uri | http://creativecommons.org/publicdomain/zero/1.0/ | * |
dc.subject | work-day loss | tr_TR |
dc.subject | vascular involvement | tr_TR |
dc.subject | ocular involvement | tr_TR |
dc.subject | Behçet's disease | tr_TR |
dc.subject.lcsh | Tıp uygulaması | tr_TR |
dc.title | Predictive factors for work-day loss in Behçet's syndrome: A multi-center study | tr_TR |
dc.type | info:eu-repo/semantics/article | tr_TR |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Int J Rheum Dis | tr_TR |
dc.contributor.department | İç Hastalıkları | tr_TR |
dc.identifier.volume | 23 | tr_TR |
dc.identifier.issue | 2 | tr_TR |
dc.identifier.startpage | 240 | tr_TR |
dc.identifier.endpage | 246 | tr_TR |
dc.description.index | PubMed | tr_TR |
dc.funding | Yok | tr_TR |